Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used for major depressive disorder are often used off-label for the management of PPD patients. These drugs include multiple well-established classes, such as SSRIs, SNRIs, mixed serotonin modulators, and atypical antipsychotics. The high unmet need for therapies specifically targeting PPD gives the first approved branded agent, Zulresso (Sage Therapeutics), an opportunity to be incorporated into the PPD treatment algorithm and creates opportunities for the new oral drug Zurzuvae (Sage Therapeutics) and for future drug developers. Given the limited treatment options available to physicians, drug marketers and developers must understand physicians’ current prescribing behavior in PPD.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PPD patients?
- How has Zulresso been integrated into the treatment algorithm, and what is its source of business?
- What percentage of PPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Zulresso, SSRIs, SNRIs, bupropion, atypical antipsychotics, mixed serotonin modulators, tricyclic antidepressants, benzodiazepines, anxiolytics, etc.
Key analyses: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flows
Key features: Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
